


Current Opinion in Biotechnology

Volume 30 December 2014
ISSN 0958-1669

Jan van der Meer & Greg N Stephanopoulos, Editors



December 2014

Chemical biotechnology

Edited by Curt R Fischer and Steffen Schaffer

Pharmaceutical biotechnology

Edited by Beth Junker and Jamey D Young

February 2015 Analytical biotechnology

April 2015 Food biotechnology • Plant biotechnology

June 2015 Energy biotechnology • Environmental biotechnology

August 2015 Nanobiotechnology • Systems biology

October 2015 Pathway Engineering

Available online at www.sciencedirect.com

ScienceDirect

Access **COBT** articles online up to one month before
they appear in your print journal www.sciencedirect.com

**CURRENT
OPINION**
www.current-opinion.com

CONTENTS

Abstracted/indexed in: BIOSIS, CAB Abstracts International, CAB Health, Chemical Abstracts, EMBASE, Index Medicus, Medline. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®

- v **Curt R Fischer and Steffen Schaffer**
Editorial overview: Chemical biotechnology: The expansion of chemical biotechnology

- viii **Beth H Junker and Jamey D Young**
Editorial overview: Pharmaceutical biotechnology: Engineering cells for high quality biopharmaceuticals production

Chemical biotechnology

Edited by Curt R Fischer and Steffen Schaffer

- 1 **Stephen Wallace and Emily P Balskus**
Opportunities for merging chemical and biological synthesis
- 9 **Emilie EL Muller, Abdul R Sheik and Paul Wilmes**
Lipid-based biofuel production from wastewater
- 17 **Brian Thompson, Tae Seok Moon and David R Nielsen**
'Hybrid' processing strategies for expanding and improving the synthesis of renewable bioproducts
- 24 **D Barrie Johnson**
Biomining – biotechnologies for extracting and recovering metals from ores and waste materials
- 32 **Sean Poust, Andrew Hagen, Leonard Katz and Jay D Keasling**
Narrowing the gap between the promise and reality of polyketide synthases as a synthetic biology platform
- 51 **Volker F Wendisch**
Microbial production of amino acids and derived chemicals: Synthetic biology approaches to strain development
- 59 **Ying Wang, Jin Yin and Guo-Qiang Chen**
Polyhydroxyalkanoates, challenges and opportunities
- 66 **Robin Geys, Wim Soetaert and Inge Van Bogaert**
Biotechnological opportunities in biosurfactant production
- 101 **Danilo Porro, Paola Branduardi, Michael Sauer and Diethard Mattanovich**
Old obstacles and new horizons for microbial chemical production
- 178 **Nadine Ladkau, Andreas Schmid and Bruno Bühler**
The microbial cell – functional unit for energy dependent multistep biocatalysis
- 190 **Mickel LA Jansen and Walter M van Gulik**
Towards large scale fermentative production of succinic acid
- 230 **Yunzi Luo, Ryan E Cobb and Huimin Zhao**
Recent advances in natural product discovery

Pharmaceutical biotechnology

Edited by Beth Junker and Jamey D Young

- 40 **Jong Youn Baik and Kelvin H Lee**
Toward product attribute control: developments from genome sequencing
- 45 **Robert P Harris and Peter M Kilby**
Amino acid misincorporation in recombinant biopharmaceutical products
- 73 **Alan J Dickson**
Enhancement of production of protein biopharmaceuticals by mammalian cell cultures: the metabolomics perspective
- 80 **Kelley M Heffner, Deniz Baycin Hizal, Amit Kumar, Joseph Shiloach, Jie Zhu, Michael A Bowen and Michael J Betenbaugh**
Exploiting the proteomics revolution in biotechnology: from disease and antibody targets to optimizing bioprocess development
- 87 **Joseph K Cheng and Hal S Alper**
The genome editing toolbox: a spectrum of approaches for targeted modification
- 95 **Richard Strasser, Friedrich Altmann and Herta Steinkellner**
Controlled glycosylation of plant-produced recombinant proteins
- 107 **Michael Butler and Maureen Spearman**
The choice of mammalian cell host and possibilities for glycosylation engineering
- 113 **Nandita Vishwanathan, Huong Le, Tung Le and Wei-Shou Hu**
Advancing biopharmaceutical process science through transcriptome analysis
- 120 **Michael A Meehl and Terrance A Stadheim**
Biopharmaceutical discovery and production in yeast
- 128 **Man-Seok Ju and Sang Taek Jung**
Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics
- 140 **Kurt Brorson and Audrey Y Jia**
Therapeutic monoclonal antibodies and consistent ends: terminal heterogeneity, detection, and impact on quality
- 147 **T Shantha Raju and Steven E Lang**
Diversity in structure and functions of antibody sialylation in the Fc



- 153 Catherine EM Hogwood, Daniel G Bracewell and C Mark Smales**
Measurement and control of host cell proteins (HCPs) in CHO cell bioprocesses
- 161 Daniel A M Pais, Manuel JT Carrondo, Paula M Alves and Ana P Teixeira**
Towards real-time monitoring of therapeutic protein quality in mammalian cell processes
- 168 Carissa L Young and Anne S Robinson**
Protein folding and secretion: mechanistic insights advancing recombinant protein production in *S. cerevisiae*
- 198 Haimanti Dorai and Subinay Ganguly**
Mammalian cell-produced therapeutic proteins: heterogeneity derived from protein degradation
- 205 Stephen RP Jaffé, Benjamin Strutton, Zdenko Levarski, Jagroop Pandhal and Phillip C Wright**
Escherichia coli as a glycoprotein production host: recent developments and challenges
- 211 Christopher J Roberts**
Protein aggregation and its impact on product quality

- 218 Philipp N Spahn and Nathan E Lewis**
Systems glycobiology for glycoengineering
- 225 Xiaoyu Yang and Alexandre Ambrogelly**
Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies
- 238 Jamey D Young**
¹³C metabolic flux analysis of recombinant expression hosts

The cover

Microbial cells offer functionalities being highly suitable for efficient multistep biocatalysis. Besides exploiting native enzymes and pathways, whole-cell biocatalysis is expanding towards the design of catalytic modules using synthetic biology and retrosynthetic approaches. Increasing substrate/product scopes and biocatalyst efficiencies illustrate the potential of whole-cell multistep biocatalysis for pharma, fine, and bulk chemical production.

Microbial cells offer functionalities being highly suitable for efficient multistep biocatalysis. Besides exploiting native enzymes and pathways, whole-cell biocatalysis is expanding towards the design of catalytic modules using synthetic biology and retrosynthetic approaches. Increasing substrate/product scopes and biocatalyst efficiencies illustrate the potential of whole-cell multistep biocatalysis for pharma, fine, and bulk chemical production.